StockData
Gyre Therapeutics, Inc. logo

Gyre Therapeutics, Inc. (GYRE) stock

GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3020% below fair value
$4.21−0.31 (-6.86%)

Close on Nov 20, 2026Market cap $469.46MP/E –Yield –

Gyre Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Gyre Therapeutics's operating income for the twelve months ending Sep 30, 2026 was -$15.55M, down 809.3% year over year. For fiscal 2025 it was $11.49M, down 28.9% from the year before. The highest annual figure on record is $16.16M in fiscal 2024.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$11.49M-28.9%
FY2024Dec 31, 2024$16.16M–
FY2023Dec 31, 2023-$67.23M-830.5%
FY2022Dec 31, 2022$9.20M–
FY2021Dec 31, 2021-$87.89M–
FY2020Dec 31, 2020-$57.37M–
FY2019Dec 31, 2019-$57.28M–
FY2018Dec 31, 2018-$33.82M–
FY2017Dec 31, 2017-$21.82M–
FY2016Dec 31, 2016-$20.42M–
FY2015Dec 31, 2015-$13.80M–
FY2014Dec 31, 2014-$7.51M–
FY2013Dec 31, 2013-$10.12M–
FY2012Dec 31, 2012-$8.14M–
FY2011Dec 31, 2011-$9.75M-174.3%
FY2010Dec 31, 2010$13.12M–
FY2009Dec 31, 2009-$40.33M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$1.52M-201.7%
Q2 FY2026Jun 30, 2026-$14.36M–
Q1 FY2026Mar 31, 2026-$9.36M-511.6%
Q4 FY2025Dec 31, 2025$9.69M+1357.3%
Q3 FY2025Sep 30, 2025$1.49M-64.7%
Q2 FY2025Jun 30, 2025-$2.24M-170.1%
Q1 FY2025Mar 31, 2025$2.27M-71.8%
Q4 FY2024Dec 31, 2024$665.00K–
Q3 FY2024Sep 30, 2024$4.23M-66.8%
Q2 FY2024Jun 30, 2024$3.19M-35.8%
Q1 FY2024Mar 31, 2024$8.07M+21.1%
Q4 FY2023Dec 31, 2023-$91.63M–
Q3 FY2023Sep 30, 2023$12.76M–
Q2 FY2023Jun 30, 2023$4.97M-90.3%
Q1 FY2023Mar 31, 2023$6.66M–
Q4 FY2022Dec 31, 2022-$22.46M–
Q3 FY2022Sep 30, 2022-$5.17M–
Q2 FY2022Jun 30, 2022$51.53M–
Q1 FY2022Mar 31, 2022-$14.70M–
Q4 FY2021Dec 31, 2021-$20.31M–
Q3 FY2021Sep 30, 2021-$25.23M–
Q2 FY2021Jun 30, 2021-$19.91M–
Q1 FY2021Mar 31, 2021-$22.44M–
Q4 FY2020Dec 31, 2020-$18.84M–
Q3 FY2020Sep 30, 2020-$16.10M–
Q2 FY2020Jun 30, 2020-$17.36M–
Q1 FY2020Mar 31, 2020-$5.07M–
Q4 FY2019Dec 31, 2019-$13.99M–
Q3 FY2019Sep 30, 2019-$13.20M–
Q2 FY2019Jun 30, 2019-$14.38M–
Q1 FY2019Mar 31, 2019-$15.71M–
Q4 FY2018Dec 31, 2018-$11.68M–
Q3 FY2018Sep 30, 2018-$8.35M–
Q2 FY2018Jun 30, 2018-$7.11M–
Q1 FY2018Mar 31, 2018-$6.68M–
Q4 FY2017Dec 31, 2017-$5.83M–
Q3 FY2017Sep 30, 2017-$5.88M–
Q2 FY2017Jun 30, 2017-$5.94M–
Q1 FY2017Mar 31, 2017-$4.17M–
Q4 FY2016Dec 31, 2016-$5.22M–

More Gyre Therapeutics figures

See a number that looks wrong?